Hypertensive drugs

{
  "query": "Hypertensive drugs",
  "lang": "en",
  "source_count": 12,
  "synthesis_text": "## Main conclusion\nACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers are the main first-line drug options for hypertension in the cited guidelines. Beta-blockers are generally not preferred as routine first-line monotherapy because they are less effective and have more side effects, but they remain appropriate in selected patients with chronic coronary syndromes, heart failure with reduced ejection fraction, or atrial fibrillation needing rate control. When monotherapy is not enough, treatment is typically escalated stepwise with additional agents; thiazide-type diuretics pair especially well with ACE inhibitors or ARBs, and spironolactone or amiloride are effective add-ons for resistant hypertension. Combination potency can be grouped into low, moderate, and high intensity according to expected blood pressure lowering.\n\n## Evidence view\n- Guideline-based first-line selection: ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers are recommended as initial options for hypertension.\n- Beta-blocker exception: beta-blockers are not favored as routine first-line monotherapy, but may be used when chronic coronary syndromes, heart failure with reduced ejection fraction, or atrial fibrillation make them clinically appropriate.\n- Class overview: the major antihypertensive categories include diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.\n- Combination effect: thiazide-type diuretics enhance the antihypertensive effect of ACE inhibitors and ARBs more than other classes do.\n- Sequencing: clinicians may start with one drug and add a second or third if blood pressure remains above goal, or stop/replace a drug if it fails, causes intolerable side effects, or leads to unsafe bloodwork changes.\n- Resistant hypertension: aldosterone excess is common, and adding spironolactone or amiloride to a standard three-drug regimen is often effective; refractory hypertension is uncontrolled blood pressure despite five or more different agents, including a long-acting thiazide-like diuretic and a mineralocorticoid receptor antagonist at maximal or maximally tolerated doses.\n- Intensity framing: combination regimens can be categorized as low, moderate, or high intensity based on expected blood pressure-lowering effect.\n\n## Decision logic\n`CHECK(patient)` comorbidities and clinical fit\n- If chronic coronary syndrome, heart failure with reduced ejection fraction, or atrial fibrillation requiring rate control → a cardioselective beta-blocker may be appropriate\n- Otherwise → choose among ACE inhibitor, ARB, or dihydropyridine calcium channel blocker as first-line therapy\n\n---\n\n`START(monotherapy)` begin with one guideline-supported agent\n- Use expected blood pressure-lowering intensity and tolerability to guide the initial choice\n- Do not treat beta-blocker monotherapy as routine first-line therapy\n\n`REASSESS(response)` after titration period\n- If blood pressure is at goal → continue\n- If blood pressure is not at goal → add another agent sequentially\n- If adverse effects or unsafe laboratory changes occur → stop or replace the offending drug\n\n---\n\n`PREFER(combo)` when combining agents\n- If using an ACE inhibitor or ARB, a thiazide-type diuretic is a particularly effective partner\n- A third drug may be added if needed to reach target blood pressure\n- The final combination can be described as low, moderate, or high intensity by expected BP lowering\n\n---\n\n`IF(resistant)` if uncontrolled on a standard three-drug regimen\n- Add spironolactone or amiloride when appropriate\n- Consider aldosterone excess as a common contributor\n- If uncontrolled despite five or more different agents, including a long-acting thiazide-like diuretic and a mineralocorticoid receptor antagonist at maximal or maximally tolerated doses → refractory hypertension\n\n`RETURN(plan)` stepwise antihypertensive therapy matched to guideline first-line choices, comorbid indications, combination efficacy, tolerability, and resistant-hypertension escalation\n\n## Analysis\nThe evidence supports a stepwise antihypertensive treatment pattern rather than a single fixed drug choice for all patients. The first decision is whether the patient has a compelling comorbidity that makes a beta-blocker useful; if not, the evidence favors ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers as the routine starting options.\n\nThe observed treatment pattern is escalation based on response. One agent is started, then a second or third is added if blood pressure remains uncontrolled. This is an observed sequencing pattern in the sources, not proof of a deliberate long-range strategy. The rationale is practical: improve blood pressure control while switching out drugs that are ineffective, poorly tolerated, or associated with unsafe laboratory changes.\n\nCombination effects matter. Thiazide-type diuretics strengthen the antihypertensive effect of ACE inhibitors and ARBs more than other classes, which supports pairing those drugs when monotherapy is insufficient. That effect is a pharmacologic interaction described in the evidence; the sources do not quantify exact blood pressure reductions in this summary.\n\nFor patients with resistant hypertension, the evidence shifts from ordinary escalation to a specific add-on approach. Aldosterone excess is common, and spironolactone or amiloride added to a standard three-drug regimen is effective for many patients. Refractory hypertension is a narrower category: it remains uncontrolled even after five or more different agents, including both a long-acting thiazide-like diuretic and a mineralocorticoid receptor antagonist at maximal or maximally tolerated doses.\n\nThe low/moderate/high intensity framing is a classification of expected blood pressure-lowering effect for combinations. It helps organize treatment strength, but the supplied evidence does not provide the numeric cutoffs or a full map of which exact combinations belong to each tier.\n\n## Uncertainties\nThe evidence here does not give numeric blood pressure-lowering ranges for the low, moderate, and high intensity categories. It also does not specify which exact combinations belong to each intensity tier. Detailed adverse effect profiles and contraindications for each drug class are not provided beyond the general point that beta-blockers have a higher side-effect profile. The evidence does not settle how to choose among ACE inhibitors, ARBs, or among different dihydropyridine calcium channel blockers when several first-line options are otherwise suitable.",
  "share_id": "c38f8c6ec115",
  "share_url": "https://lightcap.ai/s/c38f8c6ec115/hypertensive-drugs",
  "json_url": "https://lightcap.ai/s/c38f8c6ec115/hypertensive-drugs/json",
  "highlights": [
    {
      "id": 1,
      "text": "ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers are the main first-line drug options for hypertension in the cited guidelines.",
      "strength": "strong",
      "source_ids": [
        1
      ],
      "source_count": 18
    },
    {
      "id": 2,
      "text": "Beta-blockers are generally not preferred as routine first-line monotherapy because they are less effective and have more side effects, but they remain appropriate in selected patients with chronic coronary syndromes, heart failure with reduced ejection fraction, or atrial fibrillation needing rate control.",
      "strength": "strong",
      "source_ids": [
        1
      ],
      "source_count": 18
    },
    {
      "id": 3,
      "text": "the major antihypertensive categories include diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.",
      "strength": "strong",
      "source_ids": [
        2
      ],
      "source_count": 18
    },
    {
      "id": 4,
      "text": "Combination potency can be grouped into low, moderate, and high intensity according to expected blood pressure lowering.",
      "strength": "strong",
      "source_ids": [
        3
      ],
      "source_count": 18
    },
    {
      "id": 5,
      "text": "treatment is typically escalated stepwise with additional agents; thiazide-type diuretics pair especially well with ACE inhibitors or ARBs, and spironolactone or amiloride are effective add-ons for resistant hypertension.",
      "strength": "strong",
      "source_ids": [
        4,
        5,
        6
      ],
      "source_count": 54
    },
    {
      "id": 6,
      "text": "ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers are the main first-line drug options for hypertension in the cited guidelines.",
      "strength": "strong",
      "source_ids": [
        1,
        7,
        2
      ],
      "source_count": 51
    },
    {
      "id": 7,
      "text": "Class overview: the major antihypertensive categories include diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.",
      "strength": "strong",
      "source_ids": [
        2,
        1,
        7
      ],
      "source_count": 51
    },
    {
      "id": 8,
      "text": "Combination effect: thiazide-type diuretics enhance the antihypertensive effect of ACE inhibitors and ARBs more than other classes do.",
      "strength": "strong",
      "source_ids": [
        6,
        9,
        5
      ],
      "source_count": 51
    },
    {
      "id": 9,
      "text": "Sequencing: clinicians may start with one drug and add a second or third if blood pressure remains above goal, or stop/replace a drug if it fails, causes intolerable side effects, or leads to unsafe bloodwork changes.",
      "strength": "strong",
      "source_ids": [
        4,
        5,
        12
      ],
      "source_count": 51
    },
    {
      "id": 10,
      "text": "Resistant hypertension: aldosterone excess is common, and adding spironolactone or amiloride to a standard three-drug regimen is often effective",
      "strength": "strong",
      "source_ids": [
        5,
        1,
        9
      ],
      "source_count": 51
    },
    {
      "id": 11,
      "text": "refractory hypertension is uncontrolled blood pressure despite five or more different agents, including a long-acting thiazide-like diuretic and a mineralocorticoid receptor antagonist at maximal or maximally tolerated doses.",
      "strength": "strong",
      "source_ids": [
        5,
        6,
        7
      ],
      "source_count": 51
    },
    {
      "id": 12,
      "text": "Thiazide-type diuretics strengthen the antihypertensive effect of ACE inhibitors and ARBs more than other classes, which supports pairing those drugs when monotherapy is insufficient.",
      "strength": "strong",
      "source_ids": [
        6,
        8,
        7
      ],
      "source_count": 51
    },
    {
      "id": 13,
      "text": "For patients with resistant hypertension, the evidence shifts from ordinary escalation to a specific add-on approach.",
      "strength": "strong",
      "source_ids": [
        5,
        7,
        11
      ],
      "source_count": 51
    },
    {
      "id": 14,
      "text": "The evidence here does not give numeric blood pressure-lowering ranges for the low, moderate, and high intensity categories.",
      "strength": "strong",
      "source_ids": [
        3,
        1,
        11
      ],
      "source_count": 51
    },
    {
      "id": 15,
      "text": "Detailed adverse effect profiles and contraindications for each drug class are not provided beyond the general point that beta-blockers have a higher side-effect profile.",
      "strength": "strong",
      "source_ids": [
        1,
        10,
        11
      ],
      "source_count": 51
    }
  ],
  "meta": {
    "search_execution": {
      "status": "completed",
      "mode": "root",
      "source_mode": "web",
      "output_mode": "synthesis",
      "query_language": "en",
      "stage": "done",
      "title": "",
      "message": "",
      "action": "",
      "recovery": false,
      "started_at": 1774290487,
      "updated_at": 1775616554,
      "completed_at": 1774290667
    },
    "follow_up": {
      "status": "ready",
      "options": [
        {
          "id": "side-effects-management",
          "label": "Side Effects and Adverse Reactions",
          "query": "common and severe side effects of major antihypertensive drug classes and clinical management strategies",
          "steps": [
            "Identify class-specific side effects for ACE inhibitors and CCBs",
            "Research metabolic impacts of thiazide diuretics and beta-blockers",
            "Find clinical protocols for managing drug-induced cough or edema",
            "Analyze contraindications for specific patient populations and comorbidities"
          ]
        },
        {
          "id": "resistant-hypertension-protocols",
          "label": "Resistant Hypertension Treatment Protocols",
          "query": "advanced pharmacological strategies and mineralocorticoid receptor antagonists for treating resistant and refractory hypertension",
          "steps": [
            "Define clinical criteria for resistant versus refractory hypertension",
            "Evaluate the efficacy of spironolactone and amiloride as add-ons",
            "Review the role of sympatholytic agents and direct vasodilators",
            "Investigate non-pharmacological interventions like renal denervation for resistant cases"
          ]
        },
        {
          "id": "combination-therapy-optimization",
          "label": "Fixed-Dose Combination Therapy Benefits",
          "query": "clinical outcomes and patient adherence rates for fixed-dose combination antihypertensive pills versus loose-pill regimens",
          "steps": [
            "Compare blood pressure lowering efficacy of dual versus triple combinations",
            "Analyze patient compliance data for single-pill combinations",
            "Research the 'polypill' concept in global hypertension management guidelines",
            "Identify optimal drug pairings for high-intensity blood pressure reduction"
          ]
        },
        {
          "id": "pharmacogenomics-precision-medic",
          "label": "Pharmacogenomics in Hypertension Treatment",
          "query": "genetic markers influencing antihypertensive drug response and personalized medicine approaches for blood pressure control",
          "steps": [
            "Identify genetic polymorphisms affecting ACE inhibitor and beta-blocker metabolism",
            "Research racial and ethnic variations in response to diuretics and CCBs",
            "Evaluate current commercial genetic testing for antihypertensive selection",
            "Assess the future of precision medicine in standard hypertension guidelines"
          ]
        }
      ],
      "selected_option_id": "",
      "selected_label": "",
      "selected_query": "",
      "selected_steps": [],
      "language": "en",
      "default_source_mode": "web",
      "generated_at": 1774290947,
      "selected_at": 0,
      "completed_at": 0,
      "depth": 0,
      "chain": []
    },
    "feedback": {
      "submitted": false,
      "vote": "",
      "text": "",
      "submitted_at": 0
    },
    "presentation_repair": {
      "contract_version": 0,
      "signature": "",
      "status": "",
      "attempted_at": 0
    },
    "presentation_context": {
      "browser_hl": "en",
      "detected_hl": "en",
      "detected_confidence": 0.0,
      "detected_ambiguous": true,
      "presentation_hl": "en",
      "detection_source": "unresolved_kept_stored",
      "resolved_at": 1775616554
    },
    "viewer_can_interact": true,
    "viewer_can_access_inputs": false
  },
  "sources": [
    {
      "id": 1,
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12161640/",
      "domain": "pmc.ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov",
      "title": "Hypertension Guidelines",
      "summary": "This article compares international guidelines from the ESC and ACE with local recommendations for managing hypertension, focusing on first-line drug choices. It notes differing views on the use of beta-blockers as initial monotherapy.",
      "summary_detail": "ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers are the main first-line drug options for hypertension in the cited guidelines.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Guideline Comparison",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 2,
      "url": "https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications",
      "domain": "heart.org",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fheart.org",
      "title": "Blood Pressure Medications",
      "summary": "This resource provides a comprehensive overview of the main classes of medications used to treat high blood pressure, including diuretics, beta-blockers, ACE inhibitors, ARBs, and calcium channel blockers.",
      "summary_detail": "the major antihypertensive categories include diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Medication Overview",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 3,
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00991-2/fulltext",
      "domain": "thelancet.com",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fthelancet.com",
      "title": "Drug Efficacy Analysis",
      "summary": "This analysis quantifies the blood pressure-lowering effects of various antihypertensive drug combinations, categorizing them by their intensity of effect – low, moderate, or high.",
      "summary_detail": "Combination potency can be grouped into low, moderate, and high intensity according to expected blood pressure lowering.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Efficacy Research",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 4,
      "url": "https://my.clevelandclinic.org/health/treatments/21811-antihypertensives",
      "domain": "my.clevelandclinic.org",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fmy.clevelandclinic.org",
      "title": "Blood Pressure Medications",
      "summary": "Doctors often adjust hypertension treatment by adding medications or switching drugs to find what works best for each patient.",
      "summary_detail": "Sequencing: clinicians may start with one drug and add a second or third if blood pressure remains above goal, or stop/replace a drug if it fails, causes intolerable side effects, or leads to unsafe bloodwork changes.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Clinical Guidance",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 5,
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6469348/",
      "domain": "pmc.ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov",
      "title": "Resistant Hypertension",
      "summary": "Treating resistant hypertension often involves adding spironolactone or amiloride to existing medications, while refractory hypertension requires using five or more drug classes.",
      "summary_detail": "Combination effect: thiazide-type diuretics enhance the antihypertensive effect of ACE inhibitors and ARBs more than other classes do.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Advanced Treatment",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 6,
      "url": "https://www.msdmanuals.com/professional/cardiovascular-disorders/hypertension/medications-for-hypertension",
      "domain": "msdmanuals.com",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fmsdmanuals.com",
      "title": "Hypertension Medications",
      "summary": "Thiazide diuretics can improve the effectiveness of ACE inhibitors and angiotensin II receptor blockers more than other types of blood pressure medication.",
      "summary_detail": "Combination effect: thiazide-type diuretics enhance the antihypertensive effect of ACE inhibitors and ARBs more than other classes do.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Drug Interactions",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 7,
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8034801/",
      "domain": "pmc.ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov",
      "title": "Hypertension Treatment Guidelines",
      "summary": "Current guidelines from the ACC/AHA recommend thiazide diuretics, calcium channel blockers, ACE inhibitors, and ARBs as first-line treatments for hypertension due to their effectiveness in lowering blood pressure and improving patient outcomes. This resource provides an overview of evidence-based recommendations for managing hypertension.",
      "summary_detail": "ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers are the main first-line drug options for hypertension in the cited guidelines.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Clinical Guidelines",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 8,
      "url": "https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480",
      "domain": "mayoclinic.org",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fmayoclinic.org",
      "title": "ACE Inhibitors Explained",
      "summary": "ACE inhibitors lower blood pressure by blocking the production of angiotensin II, a hormone that constricts blood vessels, ultimately reducing the heart's workload. This mechanism makes them a valuable treatment option for hypertension and related conditions.",
      "summary_detail": "Thiazide-type diuretics strengthen the antihypertensive effect of ACE inhibitors and ARBs more than other classes, which supports pairing those drugs when monotherapy is insufficient.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Drug Mechanism",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 9,
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6924620/",
      "domain": "pmc.ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov",
      "title": "Antihypertensive Drug Comparison",
      "summary": "This research systematically compares the effectiveness and safety of different first-line antihypertensive drug classes in reducing cardiovascular and kidney-related risks. The study addresses limitations in existing clinical trial data to provide a more comprehensive assessment.",
      "summary_detail": "Combination effect: thiazide-type diuretics enhance the antihypertensive effect of ACE inhibitors and ARBs more than other classes do.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Comparative Research",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 10,
      "url": "https://www.medicalnewstoday.com/articles/323724",
      "domain": "medicalnewstoday.com",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fmedicalnewstoday.com",
      "title": "Blood Pressure Medications",
      "summary": "This article details the different types of medications used to treat high blood pressure and their potential side effects.",
      "summary_detail": "Detailed adverse effect profiles and contraindications for each drug class are not provided beyond the general point that beta-blockers have a higher side-effect profile.",
      "date": "",
      "flag": "",
      "source_country": "",
      "source_language": "",
      "connector": "Medical Information",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 11,
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10397146/",
      "domain": "pmc.ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov",
      "title": "Combining Hypertension Drugs",
      "summary": "This research explores the use of beta-blockers and ACE inhibitors together to treat high blood pressure, examining how they interact and the evidence supporting their combined use.",
      "summary_detail": "For patients with resistant hypertension, the evidence shifts from ordinary escalation to a specific add-on approach.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Research Study",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    },
    {
      "id": 12,
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK554579/",
      "domain": "ncbi.nlm.nih.gov",
      "favicon": "https://www.google.com/s2/favicons?sz=64&domain_url=https%3A%2F%2Fncbi.nlm.nih.gov",
      "title": "Antihypertensive Medication Options",
      "summary": "This resource provides a detailed overview of medications used to treat hypertension, categorizing them by their role as first, second, or third-line treatments.",
      "summary_detail": "Sequencing: clinicians may start with one drug and add a second or third if blood pressure remains above goal, or stop/replace a drug if it fails, causes intolerable side effects, or leads to unsafe bloodwork changes.",
      "date": "",
      "flag": "🇺🇸",
      "source_country": "US",
      "source_language": "",
      "connector": "Clinical Reference",
      "presentation_ready": true,
      "presentation_version": 3,
      "presentation_hl": "en"
    }
  ],
  "follow_up_turn": {
    "query": "Hypertensive drugs",
    "label": "",
    "synthesis_text": "",
    "results": [],
    "highlights": [],
    "attachments": [],
    "attachment_context": ""
  },
  "viewer_can_interact": true,
  "viewer_can_access_inputs": false
}